Latin America insulin market was valued at US$ 2,855.1 million in 2022 and is projected to attain a valuation of US$ 3,857.50 million by 2031 at a CAGR of 3.4% during the forecast period 2023–2031.
The global hyaluronidase market exhibited a valuation of US$ 778.37 million in 2022, and it is projected to reach a market valuation of US$ 1,894.03 million by 2031, with a compound annual growth rate (CAGR) of 9.3% during the forecast period of 2023-2031.
Saudi Arabia generic pharmaceutical products market was valued at US$ 3,222.83 million in 2022 and is projected to attain a valuation of US$ 5,315.78 million by 2031 at a CAGR of 5.85% during the forecast period.
Global hyoscine-n-butyl bromide market was valued at US$ 55.2 million in 2022 and is projected to attain a valuation of US$ 85.7 million by 2031 at a CAGR of 4.98% during the forecast period 2023–2031.
The global BCG tuberculosis vaccine market was valued at US$63.58 million in 2022 and is expected to attain a market valuation of US$ 91.10 million by 2031, at a CAGR of 4.5% during the forecast period (2023-2031).
The global anthrax vaccine market is expected to grow at a steady CAGR of 6.7%, fueled by increasing bioterrorism threats and growing awareness about the disease. As of 2022, the market was valued at US$ 599 million and is expected to surpass valuation of US$ 1,006.33 million by 2031.
The global age-related macular degeneration market was valued at US$ 10.55 billion in 2022 and is expected to reach market size of US$ 18.40 million by 2031 at a CAGR of 7.2% during the forecast period 2023–2031.
Global chronic pain management market was valued at US$ 93.31 billion in 2022 and is expected to attain market size of US$ 168.68 billion by 2031 at a CAGR of 6.8% during the forecast period 2023–2031.
The global real world evidence solutions market has seen substantial growth, spurred by rising demand for medical insights, the surge in healthcare data digitization, and increased chronic disease prevalence. As of 2022, the market size was USD 1,522.2 million in 2022, projected to reach USD 5,810.6 billion by 2031, growing at a CAGR of 16.5% during the forecast period.
Global genomics personalized health market was valued at US$ 14.9 billion in 2022 and is projected to attain a valuation of US$ 44.4 billion by 2031 at a CAGR of 14.6% during the forecast period 2023–2031.
